Literature DB >> 2827051

Reoperation in the treatment of recurrent intracranial malignant gliomas.

M Ammirati1, J H Galicich, E Arbit, Y Liao.   

Abstract

Fifty-five consecutive patients with recurrent intracranial malignant gliomas were reoperated at Memorial Sloan-Kettering Cancer Center from 1972 to 1983. The patients were 10 to 70 years old (median, 48 years). Thirty-five patients (64%) had glioblastoma multiforme, and 20 (36%) had anaplastic astrocytoma. The median interval between the first operation and reoperation was 43 weeks. The Karnofsky rating before reoperation ranged from 40 to 90 (median, 70). Eleven patients (20%) had more than one reoperation. The mortality rate was 1.4% per procedure, and the morbidity rate was 16% per procedure. After reoperation, 41 patients (75%) had chemotherapy and/or radiation therapy. The median survival for all patients was 92 weeks. The median survival after reoperation was 36 weeks. Patients with Karnofsky ratings of greater than or equal to 70, with anaplastic astrocytomas, or in whom gross total removal of the tumor was undertaken lived longer than their respective counterparts (P less than 0.05). Prereoperation Karnofsky rating and extent of surgical resection were the most important independent factors related to survival after reoperation according to multivariate analysis (P less than 0.01 and P less than 0.05, respectively). Twenty-five patients (45%) had improved Karnofsky ratings after reoperation, and the 32 patients (58%) who were independent after reoperation were able to stay so for more than 6 months of their survival time (median value). Reoperation is feasible and can be accomplished with acceptable mortality and morbidity. When intracranial malignant gliomas recur, the combined use of reoperation and adjuvant therapy prolongs good quality life.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1987        PMID: 2827051     DOI: 10.1227/00006123-198711000-00001

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  53 in total

Review 1.  Historical development of surgery for glial tumors.

Authors:  M Salcman
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

2.  Scale to predict survival after surgery for recurrent glioblastoma multiforme.

Authors:  John K Park; Tiffany Hodges; Leopold Arko; Michael Shen; Donna Dello Iacono; Adrian McNabb; Nancy Olsen Bailey; Teri Nguyen Kreisl; Fabio M Iwamoto; Joohee Sul; Sungyoung Auh; Grace E Park; Howard A Fine; Peter McL Black
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

3.  Prognostic significance of preoperative MRI scans in glioblastoma multiforme.

Authors:  M A Hammoud; R Sawaya; W Shi; P F Thall; N E Leeds
Journal:  J Neurooncol       Date:  1996-01       Impact factor: 4.130

4.  Treatment of malignant recurrent glioma by intra-arterial, infra-ophthalmic infusion of HECNU 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl) urea. A phase II study.

Authors:  M Poisson; J Chiras; F Fauchon; C Debussche; J Y Delattre
Journal:  J Neurooncol       Date:  1990-06       Impact factor: 4.130

Review 5.  Treatment options for recurrent high-grade gliomas.

Authors:  Harjus S Birk; Seunggu J Han; Nicholas A Butowski
Journal:  CNS Oncol       Date:  2016-12-21

6.  Outcome of radiosurgery for recurrent malignant gliomas: assessment of treatment response using relative cerebral blood volume.

Authors:  Hong Rye Kim; Se-Hwan Kim; Jung-Il Lee; Ho Jun Seol; Do-Hyun Nam; Sung Tae Kim; Kwan Park; Jong Hyun Kim; Doo-Sik Kong
Journal:  J Neurooncol       Date:  2014-12-09       Impact factor: 4.130

7.  Intra-operative radiation therapy for malignant brain tumors: rationale, method, and treatment results of cerebral glioblastomas.

Authors:  M Matsutani; O Nakamura; T Nagashima; A Asai; T Fujimaki; H Tanaka; M Nakamura; K Ueki; Y Tanaka; T Matsuda
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

8.  Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression.

Authors:  Mairéad G McNamara; Zarnie Lwin; Haiyan Jiang; Arnoud J Templeton; Gelareh Zadeh; Mark Bernstein; Caroline Chung; Barbara-Ann Millar; Normand Laperriere; Warren P Mason
Journal:  J Neurooncol       Date:  2014-01-28       Impact factor: 4.130

9.  Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?

Authors:  Amerigo Boiardi; Antonio Silvani; Marica Eoli; Elena Lamperti; Andrea Salmaggi; Paola Gaviani; Anna Fiumani; Andrea Botturi; Chiara Falcone; Alessandra Solari; Graziella Filippini; Francesco Di Meco; Giovanni Broggi
Journal:  J Neurooncol       Date:  2008-02-19       Impact factor: 4.130

10.  BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors.

Authors:  Thomas Reithmeier; Erika Graf; Tobias Piroth; Michael Trippel; Marcus O Pinsker; Guido Nikkhah
Journal:  BMC Cancer       Date:  2010-02-02       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.